Ganga Pharmaceuticals Peer Comparison

Ganga Pharmaceuticals Ltd. is currently underperforming compared to its peers in terms of growth and profitability, with no revenue or earnings recorded. However, it has a low debt-to-equity ratio, positioning it as a potential deep value pick amid a sector with several strong performers like Sun Pharmaceutical Industries and Cipla, which exhibit robust growth and profitability metrics.

• • Ganga Pharmaceuticals shows no growth or profitability metrics, making it a passive player in the sector.
• • Sun Pharmaceuticals and Cipla stand out as sector leaders with strong earnings and growth rates.
• • Target company has a very low debt level, making it less financially risky compared to peers.

• • Sun Pharmaceutical Industries Ltd.: Highest revenue growth YoY at 8.42% and strong profitability with an ROE of 16.13%.
• • Cipla Ltd.: Robust growth with 13.28% revenue growth YoY and very attractive PE ratio of 23.73.
• • Mankind Pharma Ltd.: Strong growth trajectory with 18.12% revenue growth YoY and solid profitability metrics.